Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 5:36 PM
Ignite Modification Date:
2025-12-25 @ 3:08 PM
NCT ID:
NCT04385368
Pre Assignment Details:
A total of 89 participants were randomized in a 1:1 ratio to durvalumab given concurrently with standard of care (SoC) chemotherapy followed by durvalumab monotherapy, or to a matched placebo given concurrently with SoC chemotherapy followed by placebo.
Recruitment Details:
This Phase III, multicenter, randomized, double-blind, placebo-controlled study was conducted in participants with completely resected stage II to III non-small cell lung cancer (NSCLC) at 63 sites across 25 countries from 17 July 2020 to 31 August 2023.
Study:
NCT04385368
Study Brief:
Results Section:
NCT04385368